Categories AlphaGraphs, Earnings, Technology
Earnings: Cisco (CSCO) Q3 2023 profit grows on higher revenues
Cisco Systems Inc. (NASDAQ: CSCO) announced results for the third quarter of 2023, reporting higher revenues and earnings. The company also provided guidance for the fourth quarter and fiscal 2023.
The San Jose-headquartered network gear maker said that earnings, excluding special items, rose to $1.00 per share in the April quarter from $0.87 per share in the same period of 2022. Unadjusted net income was $3.21 billion or $0.78 per share, compared to last year’s profit of $3.04 billion or $0.73 per share.
At $14.57 billion, third-quarter revenues were up 14% year-over-year. The top line benefitted from strong contributions from the core Secure, Agile Networks division.
“In Q3, we delivered record revenue and double-digit growth in both software and subscription revenue. As key technologies like cloud, AI and security continue to scale, Cisco’s long-established leadership in networking, and the breadth of our portfolio position us well for the future,” said Cisco’s CEO Chuck Robbins.
Prior Performance
_________________________________________________________________________________________________________________
Stocks you may like:
International Business Machines Corp. (IBM) Stock
_________________________________________________________________________________________________________________
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs
